arrow
A

Andrew A. Davis

Washington University in St. Louis
H指数:31
被引数:6,003

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling

在转移性乳腺癌中整合机器学习预测的循环肿瘤细胞 (ctc) 和循环肿瘤DNA (ctDNA): 内分泌耐药分析的原理研究证明

2025-01-010
PRE
Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors

B7-H4靶向抗体药物偶联物(ADC)AZD8205(puxitatug samrotecan)在晚期/转移性实体瘤患者中的首次人体研究的初步结果

2024-09-011
PRE
Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522
2024-05-020
PRE
Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer
2024-05-020
PRE
Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium
2024-05-020
PRE
Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA
2024-05-020
PRE
Genomic landscape characterization after exposure to cyclin dependent kinase 4/6 inhibitors: a retrospective multi-institutional consortium analysis
2024-05-020
PRE
Germline BRCA1/2 mutations detected by circulating tumor DNA testing in breast cancer patients: A retrospective mutiinstitutional analysis
2024-03-220
PRE
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
2023-10-024
OAAI
TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity
2023-03-011
PRE